نتایج جستجو برای: thalidomide
تعداد نتایج: 3195 فیلتر نتایج به سال:
PURPOSE To evaluate thalidomide in advanced hepatocellular carcinoma (HCC) and to evaluate combined thalidomide and low-dose interferon-alpha2a (IFN-alpha2a) after tumor progression on thalidomide. Systemic therapy is minimally effective in HCC and tumor angiogenesis is a potential therapeutic target. PATIENTS AND METHODS Patients with unresectable HCC were eligible if they had preserved hepa...
Although thalidomide has been shown to improve anemia in some patients with myelodysplastic syndromes and stimulates erythropoietin in patients with multiple myeloma, thalidomide’s specific effects on -globin gene expression during erythroid differentiation have not been studied. Here, we investigated the effects of thalidomide on -globin gene expression and the involved signaling pathway using...
Background and Aim: Gastric antral vascular ectasia (GAVE) is a rare cause of upper gastrointestinal bleeding in cirrhotic. The first-line treatment endotherapy with argon plasma coagulation (APC). albeit high recurrence rate, Recent evidence suggests that thalidomide could play an important role controlling refractory anemia due to GAVE. Case Report: authors present the case series four cirrho...
Editorial Lenalidomide (Revlimid ®) is a synthetic derivative of thalidomide (Thalomid ®) currently licensed by the US Food and Drug Administration (FDA) and other international regulatory agencies for the treatment of multiple myeloma (MM) (in combination with dexamethasone) 1-3 and low or intermediate-1 risk myelodysplastic syndromes bearing 5q cytogenetic abnormalities (as a standalone agent...
BACKGROUND Thalidomide has been successful use in patients with refractory Crohn disease (CD) in recent years. METHODS We collected the data of a postoperative CD patient who was prescribed thalidomide to induce remission and reviewed the relevant literatures. RESULTS A 51-year-old female was diagnosed as CD after an urgent terminal intestinal resection and presented endoscopic recurrence d...
Stability of Thalidomide in Human Plasma To the Editor: Thalidomide was initially introduced into medical use in the 1950s as a sedative; because of its terato-genie effects (malformation of the extremities), however, it was withdrawn from the market. Chronic use of thalidomide was also associated with peripheral neuritis. Lately, interest in thalidomide has renewed after demonstration of its a...
by thalidomide requires metabolic activation, which is species dependent. Biochem Pharmacol 1998; 55: 182734. 10. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high grade gliomas. J Clin Oncol 2000; 18:708-15. 11. Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, et al. Phas...
BACKGROUND Inflammation and matrix degradation may play a pathogenic role in chronic heart failure (CHF), and therefore, we examined whether thalidomide, a drug with potential immunomodulating and matrix-stabilizing properties, could improve left ventricular (LV) function in patients with CHF secondary to idiopathic dilated cardiomyopathy (IDCM) or coronary artery disease (CAD). METHODS AND R...
Thalidomide is an efficient anti-inflammatory and anti-angiogenic drug, but its therapeutic use is problematic due to a strong teratogenic activity. Nevertheless, thalidomide was approved for the treatment of inflammatory skin diseases and certain types of cancer, and it is extensively tested for several other indications. Recently, we demonstrated that active caspase-1, whose activation is dep...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید